Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1881683

Post Menopausal Osteoporosis - Pipeline Review, H2 2011

Description:

Post Menopausal Osteoporosis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Post Menopausal Osteoporosis - Pipeline Review, H2 2011', provides an overview of the Post Menopausal Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. 'Post Menopausal Osteoporosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post Menopausal Osteoporosis.
- A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post Menopausal Osteoporosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Post Menopausal Osteoporosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis Overview
Therapeutics Development
An Overview of Pipeline Products for Post Menopausal Osteoporosis
Post Menopausal Osteoporosis Therapeutics under Development by Companies
Post Menopausal Osteoporosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Post Menopausal Osteoporosis Therapeutics - Products under Development by Companies
Post Menopausal Osteoporosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Post Menopausal Osteoporosis Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Merck & Co., Inc.
Ablynx
Novartis AG
Chiesi Farmaceutici SpA
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Zosano Pharma, Inc.
Ligand Pharmaceuticals Incorporated
NPS Pharmaceuticals, Inc.
Osteologix, Inc.
Unigene Laboratories, Inc.
Uni-Bio Science Group Ltd.
Intas Pharmaceuticals Ltd.
Acceleron Pharma, Inc.
EffRx, Inc.
Radius Health, Inc.
Tarsa Therapeutics, Inc.
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 785 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACE-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SMC021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PREOS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Boniva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EX101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Recombinant Parathyroid Hormone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB S101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGD-4033 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH Analogs Oral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sCT oral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Parathyroid Hormone-Related Protein (1-36) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fablyn - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-5334 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHF4227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Denosumab + Teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Risedronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZP-PTH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zosano PTH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bonviva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actonel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosamax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Letrozole + Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tibolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-5442 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BA058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Denosumab + Alendronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 + Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcitonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UNI-PH (1-34) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates
Post Menopausal Osteoporosis Therapeutics - Discontinued Products
Post Menopausal Osteoporosis - Featured News
Aug 18, 2011: Amgen To Present Data From Prolia Studies At American Society For Bone And Mineral Research Meeting
Jul 12, 2011: Tarsa Therapeutics Advances Oral Calcitonin For Treatment And Prevention Of Postmenopausal Osteoporosis
Jun 17, 2011: Emisphere Receives Notice Of Results From Collaborator's Proof Of Concept Study For Oral PTH For Treatment Of Postmenopausal Osteoporosis
May 25, 2011: Ablynx To Present Clinical Data On Anti-RANKL Nanobody, ALX-0141 At Annual European Congress Of Rheumatology
May 11, 2011: EffRx Receives FDA Approval For NDA Filling Of EX101
Apr 27, 2011: Unigene Laboratories Completes Patient Enrollment Of Oral PTH Phase II Study For Treatment Of Osteoporosis In Postmenopausal Women
Apr 21, 2011: Amgen And UCB Announce Positive Phase II Results Of AMG 785/CDP7851 In Patients With Postmenopausal Osteoporosis
Mar 24, 2011: Tarsa Reports Positive Top-Line Results From Pivotal Phase III Oracal Trial Of Oral Calcitonin
Mar 23, 2011: Amgen Announces New Encouraging Data From Two-Year Open-Label Study Of Prolia
Mar 23, 2011: Amgen Announces New Long-Term Data From Open-Label Extension Trial Of Prolia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Post Menopausal Osteoporosis, H2 2011
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
Merck & Co., Inc., 2011
Ablynx, 2011
Novartis AG, 2011
Chiesi Farmaceutici SpA, 2011
Ono Pharmaceutical Co., Ltd., 2011
Pfizer Inc., 2011
Zosano Pharma, Inc., 2011
Ligand Pharmaceuticals Incorporated, 2011
NPS Pharmaceuticals, Inc., 2011
Osteologix, Inc., 2011
Unigene Laboratories, Inc., 2011
Uni-Bio Science Group Ltd., 2011
Intas Pharmaceuticals Ltd., 2011
Acceleron Pharma, Inc., 2011
EffRx, Inc., 2011
Radius Health, Inc., 2011
Tarsa Therapeutics, Inc., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H2 2011
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Friday, May 24, 2013
9:45:11 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Post Menopausal Osteoporosis - Pipeline Review, H2 2011

Web Address

http://www.researchandmarkets.com/reports/1881683

Office Code

OC8DIQSNPRRXXX

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Friday, May 24, 2013
9:45:11 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Post Menopausal Osteoporosis - Pipeline Review, H2 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)